Ye Sang Ho, Johnson Carl A, Woolley Joshua R, Oh Heung-Il, Gamble Lara J, Ishihara Kazuhiko, Wagner William R
McGowan Institute for Regenerative Medicine, University of Pittsburgh, 100 Technology Dr., Suite 200, Pittsburgh, PA 15219, USA.
Colloids Surf B Biointerfaces. 2009 Nov 1;74(1):96-102. doi: 10.1016/j.colsurfb.2009.06.032. Epub 2009 Jul 7.
To improve the thromboresistance of a titanium alloy (TiAl(6)V(4)) surface which is currently utilized in several ventricular assist devices (VADs), a plasma-induced graft polymerization of 2-methacryloyloxyethyl phosphorylcholine (MPC) was carried out and poly(MPC) (PMPC) chains were covalently attached onto a TiAl(6)V(4) surface by a plasma induced technique. Cleaned TiAl(6)V(4) surfaces were pretreated with H(2)O-vapor-plasma and silanated with 3-methacryloylpropyltrimethoxysilane (MPS). Next, a plasma-induced graft polymerization with MPC was performed after the surfaces were pretreated with Ar plasma. Surface compositions were verified by X-ray photoelectron spectroscopy (XPS). In vitro blood biocompatibility was evaluated by contacting the modified surfaces with ovine blood under continuous mixing. Bulk phase platelet activation was quantified by flow cytometric analysis, and surfaces were observed with scanning electron microscopy after blood contact. XPS data demonstrated successful modification of the TiAl(6)V(4) surfaces with PMPC as evidenced by increased N and P on modified surfaces. Platelet deposition was markedly reduced on the PMPC grafted surfaces and platelet activation in blood that contacted the PMPC-grafted samples was significantly reduced relative to the unmodified TiAl(6)V(4) and polystyrene control surfaces. Durability studies under continuously mixed water suggested no change in surface modification over a 1-month period. This modification strategy shows promise for further investigation as a means to reduce the thromboembolic risk associated with the metallic blood-contacting surfaces of VADs and other cardiovascular devices under development.
为提高目前在几种心室辅助装置(VAD)中使用的钛合金(TiAl(6)V(4))表面的抗血栓性,进行了2-甲基丙烯酰氧乙基磷酰胆碱(MPC)的等离子体诱导接枝聚合反应,并通过等离子体诱导技术将聚(MPC)(PMPC)链共价连接到TiAl(6)V(4)表面。清洁后的TiAl(6)V(4)表面先用H(2)O-蒸汽等离子体预处理,然后用3-甲基丙烯酰丙基三甲氧基硅烷(MPS)进行硅烷化处理。接下来,在表面用Ar等离子体预处理后,进行MPC的等离子体诱导接枝聚合反应。通过X射线光电子能谱(XPS)验证表面组成。通过在连续混合条件下使改性表面与羊血接触来评估体外血液生物相容性。通过流式细胞术分析对整体血小板活化进行定量,并在血液接触后用扫描电子显微镜观察表面。XPS数据表明,改性表面上N和P的增加证明了PMPC对TiAl(6)V(4)表面的成功改性。与未改性的TiAl(6)V(4)和聚苯乙烯对照表面相比,PMPC接枝表面上的血小板沉积明显减少,与PMPC接枝样品接触的血液中的血小板活化也显著降低。在连续混合水条件下的耐久性研究表明,在1个月的时间内表面改性没有变化。这种改性策略有望作为一种手段进一步研究,以降低与VAD和其他正在开发的心血管装置的金属血液接触表面相关的血栓栓塞风险。